dl 922947
Alternative Names: dl-922947Latest Information Update: 22 Aug 2002
At a glance
- Originator Bayer HealthCare Pharmaceuticals; Chiron Corporation; Onyx Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Aug 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 11 Dec 2000 Preclinical development for Cancer in USA (Unknown route)